FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2799467144> ?p ?o ?g. }

• W2799467144 abstract "Abstract Background Cost-effectiveness of once-daily umeclidinium bromide (UMEC) was compared with once-daily tiotropium (TIO) and once-daily glycopyrronium (GLY) in patients with chronic obstructive pulmonary disease (COPD) from a UK National Health Service (NHS) perspective. Methods A linked-equation model was implemented to estimate COPD progression, associated healthcare costs, exacerbations rates, life years (LY) and quality-adjusted LY (QALYs). Statistical risk equations for endpoints and resource use were derived from the ECLIPSE and TORCH studies, respectively. Treatment effects [mean (standard error)] at 12 weeks on forced expiratory volume in 1 s and St George’s Respiratory Questionnaire score were obtained from the intention-to-treat populations of two head-to-head studies [GSK study identifiers 201316 (NCT02207829) and 201315 (NCT02236611)] which compared UMEC 62.5 mcg with TIO 18 mcg and UMEC 62.5 mcg with GLY 50 mcg, respectively. Treatment costs reflect UK list prices (2016) and NHS unit costs; UMEC and GLY prices being equal and less than TIO. A lifetime horizon, discounted costs and effects at 3.5% were used. Sensitivity analyses were performed to evaluate the robustness of variations in input parameters and assumptions in the model. Results Over a lifetime horizon, UMEC was predicted to increase LYs (+ 0.195; 95% confidence interval [CI]: 0.069, 0.356) and QALYs (+ 0.118; 95% CI: 0.055, 0.191) and reduce the number of annual exacerbations (− 0.053; 95% CI: − 0.171, 0.028) compared with TIO, with incremental cost savings of £460/patient (95% CI: − £645, − £240). Compared with GLY, UMEC increased LYs (+ 0.124; 95% CI: 0.015, 0.281) and QALYs (+ 0.101; 95% CI: 0.043, 0.179) and reduced annual exacerbation (− 0.033; 95% CI: − 0.135, 0.017) at an additional cost of £132/patient (95% CI: £12, £330), resulting in an incremental cost-effectiveness ratio of £1310/QALY (95% CI: £284, £2060). Similar results were observed in alternative time horizons and additional sensitivity analyses. Conclusions For treatment of patients with COPD in the UK over a lifetime horizon, treatment with UMEC dominates treatment with TIO, providing both improved health outcomes and cost savings. In comparison with GLY, treatment with UMEC achieved improved health outcomes but was associated with a higher cost. Trial registration 201316, NCT02207829; 201315, NCT02236611" @default.
• W2799467144 created "2018-05-17" @default.
• W2799467144 creator A5019479654 @default.
• W2799467144 creator A5031372755 @default.
• W2799467144 creator A5044410034 @default.
• W2799467144 creator A5048130857 @default.
• W2799467144 creator A5058947386 @default.
• W2799467144 creator A5067651492 @default.
• W2799467144 creator A5087152114 @default.
• W2799467144 date "2018-05-10" @default.
• W2799467144 modified "2023-10-06" @default.
• W2799467144 title "Cost-effectiveness of umeclidinium compared with tiotropium and glycopyrronium as monotherapy for chronic obstructive pulmonary disease: a UK perspective" @default.
• W2799467144 cites W1277484869 @default.
• W2799467144 cites W1768394073 @default.
• W2799467144 cites W1889449109 @default.
• W2799467144 cites W2004200914 @default.
• W2799467144 cites W2006430543 @default.
• W2799467144 cites W2023136584 @default.
• W2799467144 cites W2026835257 @default.
• W2799467144 cites W2069006515 @default.
• W2799467144 cites W2096723137 @default.
• W2799467144 cites W2102590607 @default.
• W2799467144 cites W2105234929 @default.
• W2799467144 cites W2111374619 @default.
• W2799467144 cites W2116400287 @default.
• W2799467144 cites W2117943611 @default.
• W2799467144 cites W2120661559 @default.
• W2799467144 cites W2123850585 @default.
• W2799467144 cites W2141034778 @default.
• W2799467144 cites W2142096203 @default.
• W2799467144 cites W2142724633 @default.
• W2799467144 cites W2144805491 @default.
• W2799467144 cites W2157662237 @default.
• W2799467144 cites W2287635305 @default.
• W2799467144 cites W2299097941 @default.
• W2799467144 cites W2313271471 @default.
• W2799467144 cites W2334564051 @default.
• W2799467144 cites W2344252281 @default.
• W2799467144 cites W2405194161 @default.
• W2799467144 cites W2419019628 @default.
• W2799467144 cites W2444230658 @default.
• W2799467144 cites W2493396323 @default.
• W2799467144 cites W2568629548 @default.
• W2799467144 cites W2596492194 @default.
• W2799467144 cites W2610348280 @default.
• W2799467144 cites W2746473595 @default.
• W2799467144 cites W2767010890 @default.
• W2799467144 doi "https://doi.org/10.1186/s12962-018-0101-3" @default.
• W2799467144 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5946544" @default.
• W2799467144 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29773969" @default.
• W2799467144 hasPublicationYear "2018" @default.
• W2799467144 type Work @default.
• W2799467144 sameAs 2799467144 @default.
• W2799467144 citedByCount "4" @default.
• W2799467144 countsByYear W27994671442018 @default.
• W2799467144 countsByYear W27994671442019 @default.
• W2799467144 countsByYear W27994671442020 @default.
• W2799467144 countsByYear W27994671442021 @default.
• W2799467144 crossrefType "journal-article" @default.
• W2799467144 hasAuthorship W2799467144A5019479654 @default.
• W2799467144 hasAuthorship W2799467144A5031372755 @default.
• W2799467144 hasAuthorship W2799467144A5044410034 @default.
• W2799467144 hasAuthorship W2799467144A5048130857 @default.
• W2799467144 hasAuthorship W2799467144A5058947386 @default.
• W2799467144 hasAuthorship W2799467144A5067651492 @default.
• W2799467144 hasAuthorship W2799467144A5087152114 @default.
• W2799467144 hasBestOaLocation W27994671441 @default.
• W2799467144 hasConcept C126322002 @default.
• W2799467144 hasConcept C2776780178 @default.
• W2799467144 hasConcept C2776968687 @default.
• W2799467144 hasConcept C2777714996 @default.
• W2799467144 hasConcept C3018587741 @default.
• W2799467144 hasConcept C44249647 @default.
• W2799467144 hasConcept C71924100 @default.
• W2799467144 hasConceptScore W2799467144C126322002 @default.
• W2799467144 hasConceptScore W2799467144C2776780178 @default.
• W2799467144 hasConceptScore W2799467144C2776968687 @default.
• W2799467144 hasConceptScore W2799467144C2777714996 @default.
• W2799467144 hasConceptScore W2799467144C3018587741 @default.
• W2799467144 hasConceptScore W2799467144C44249647 @default.
• W2799467144 hasConceptScore W2799467144C71924100 @default.
• W2799467144 hasIssue "1" @default.
• W2799467144 hasLocation W27994671441 @default.
• W2799467144 hasLocation W27994671442 @default.
• W2799467144 hasLocation W27994671443 @default.
• W2799467144 hasLocation W27994671444 @default.
• W2799467144 hasLocation W27994671445 @default.
• W2799467144 hasLocation W27994671446 @default.
• W2799467144 hasLocation W27994671447 @default.
• W2799467144 hasOpenAccess W2799467144 @default.
• W2799467144 hasPrimaryLocation W27994671441 @default.
• W2799467144 hasRelatedWork W1879798697 @default.
• W2799467144 hasRelatedWork W1928394001 @default.
• W2799467144 hasRelatedWork W2168449172 @default.
• W2799467144 hasRelatedWork W2325695631 @default.
• W2799467144 hasRelatedWork W2362299873 @default.
• W2799467144 hasRelatedWork W2372071230 @default.
• W2799467144 hasRelatedWork W2399217294 @default.
• W2799467144 hasRelatedWork W2808400781 @default.
• W2799467144 hasRelatedWork W2970099694 @default.

• next